A controlled trial of Acamprosate to reduce the severity of neurocognitive impairment during alcohol with
Not Applicable
- Conditions
- Cognitive impairment in heavy alcohol drinking personsNeurological - DementiasMental Health - Addiction
- Registration Number
- ACTRN12611000818932
- Lead Sponsor
- Drug and Alcohol Services South Australia
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
1.Aged 30 years or greater.
2.Have a diagnosis of DSM IV Alcohol Dependence.
3.Drinking alcohol >80gm daily in males and 60gms daily in females
Exclusion Criteria
1.Opiate, Stimulant, Cannabis, Inhalant or Benzodiazepine dependence.
2.History of dementia or severe brain injury resulting in a mini mental score less than or equal to 26 out of 30
3.Diagnosis of Wernicke’s Encephalopathy or Korsakoff’s Encephalopathy
4.Receiving Acamprosate medication in the 28 days prior to admission
5.Any history, clinical or biochemical indication of renal function impairment
6.Pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Computerized cognitive testing at day four of treatment to measure Verbal Memory,Visual Memory and Executive Function[Day 4 of treatment]
- Secondary Outcome Measures
Name Time Method The Nine Hole Peg Test a measure of ataxia to determine the time this test takes for completion[Day four of treatment]